Cirrhosis Serum

Cirrhosis Serum for Fibrotic Liver Disease Research

Our Cirrhosis Serum is sourced from IRB-consented donors clinically diagnosed with cirrhosis. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality. Serum is acellular, so this product is intended for soluble-analyte measurement rather than cell-based assays.

Cirrhosis Pathophysiology and Why Serum

Cirrhosis is the end stage of chronic liver injury from any cause. It is defined structurally, by diffuse fibrosis and regenerative nodule formation that replace normal hepatic architecture.

• Persistent hepatocyte injury activates hepatic stellate cells into matrix-secreting myofibroblasts, and the resulting collagen deposition and vascular remodelling become largely irreversible at the cirrhotic stage
• Distorted architecture raises intrahepatic vascular resistance, producing portal hypertension, which drives varices, ascites and other decompensating events
• Loss of synthetic function is directly measurable in serum: albumin falls, INR rises as clotting factor production declines, and bilirubin rises with impaired conjugation and excretion
• Aetiology varies and matters for study design: viral hepatitis, alcohol-related liver disease, metabolic steatohepatitis, and autoimmune or cholestatic causes such as primary biliary cholangitis all converge on the same structural endpoint by different routes
• Serum supports the standard staging inputs (bilirubin, albumin, INR, creatinine) used in Child-Pugh and MELD scoring, plus non-invasive fibrosis marker panels
• Serum is the appropriate matrix for aminotransferases, ammonia-adjacent metabolic markers, extracellular matrix turnover markers, and proteomic discovery in advanced liver disease

Donor Stratification Available

• Aetiology: viral hepatitis, alcohol-related, metabolic steatohepatitis, or autoimmune/cholestatic including primary biliary cholangitis
• Compensated versus decompensated disease
• Child-Pugh class where documented
• MELD score where available
• Presence of complications such as ascites, varices, or hepatic encephalopathy
• Comorbid hepatocellular carcinoma status
• Matched healthy controls available

Product Features

• Collected from clinically confirmed Cirrhosis donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Standard and custom volumes available

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and ethnicity
• Donor-reported medical history and comorbidities
• Aetiology and liver function test results where available

Applications

• Non-invasive fibrosis biomarker discovery and validation
• Serum cytokine and protein profiling
• Liver function and synthetic capacity marker measurement
• Extracellular matrix turnover marker quantification
• Serum proteomics and metabolomics in advanced liver disease
• Portal hypertension and decompensation biomarker research
• Diagnostic and staging assay development
• Therapeutic candidate screening and validation

Other Cirrhosis Specimen Types

• Cirrhosis Plasma
• Cirrhosis Whole Blood
• Cirrhosis PBMC
• Cirrhosis Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Cirrhosis serum is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse serum from other disease states and check live stock status, visit our human serum page.